Diabetes therapy
Research conducted by Shandong University has shed light on the effectiveness of family doctor contract services in managing chronic diseases such as hypertension and diabetes in a remote multi-ethnic province of China. The study, which utilized data from the 2023 Hainan Health Service Survey, found that patients who contracted a
Diabetes therapy
As the world grapples with the increasing prevalence of obesity and diabetes, researchers from the Shenzhen Center for Chronic Disease Control, in collaboration with other institutions, have conducted a 60-year study using interpretable machine learning to understand the trends and drivers of type 2 diabetes mellitus (T2DM) burden among the
Diabetes therapy
L-Nutra, a global leader in longevity and nutrition science, has been recognized as a top vendor by Shortlister in both corporate weight management and diabetes management programs. The company's patented programs combine comprehensive clinical oversight, measurable biometrics, and science-backed nutrition therapies to address chronic disease at its root.
Diabetes therapy
Researchers at the CSIR - Central Institute of Medicinal and Aromatic Plants (CIMAP) have conducted a study to investigate the efficacy of a steroidal glycoside-rich extract from fenugreek seeds against obesity-induced insulin resistance and inflammation. The study, published in the journal Food Research International, found that the extract, known as
Diabetes research
Type 2 diabetes individuals admitted to the intensive care unit with sepsis are at a higher risk of mortality due to glycemic variability, according to a recent study. Researchers retrospectively analyzed data from 233 patients with type 2 diabetes and sepsis, finding that those with high glycemic variability had a
Diabetes therapy
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising treatment for Type 2 diabetes mellitus (T2DM), obesity, and various metabolic and neurological disorders. This review explores tirzepatide's mechanisms of action, clinical efficacy, and safety profile, highlighting its potential to
Body mass index
Investigations into serum Neuromedin U (NmU) levels in patients with Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) have yielded new findings, indicating a lack of significant difference between diabetic patients and healthy controls. The study, conducted by researchers at Bursa Uludag University, involved 134 participants across three groups:
Diabetes therapy
Current research has shed light on the potential impact of tirzepatide, a dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) co-agonist, in treating type 2 diabetes and obesity. Studies have demonstrated that tirzepatide significantly reduces HbA1c levels and induces weight loss in diverse patient populations, with gastrointestinal
Health care industry
People with intellectual and developmental disabilities (IDD) are disproportionately affected by diabetes, with an estimated 16.2% of disabled Americans diagnosed with the disease, compared to 11.6% of the general population. Diagnosed diabetes cases in people with IDD are often complicated by sensory sensitivities, communication barriers, and the need
Health care industry
Renalytix PLC, a diagnostics group, has seen its shares rise by 45% in early London trading following an agreement with US health technology company Tempus AI to expand access to its flagship kidneyintelX.dkd test. The partnership will make the blood test available across Tempus's network of American
Health care industry
A growing health concern in the Philippines, with 39 percent of Filipino adults or about four of 10 Filipinos aged 20 to 59 living with obesity, has prompted global health care company Novo Nordisk to strengthen its efforts in curbing the climbing obesity incidence. In a recent partnership with Watsons
Health care industry
Investigators at the University of Texas Southwestern Medical Center have published a study comparing glycemic control achieved during pregnancy by people with type 1 diabetes using automated insulin delivery (AID) systems versus standard of care therapy. The research found that AID systems improved time in range (TIR) and reduced time
